EXACT Sciences Co. (EXAS) Insider Kevin T. Conroy Sells 101,488 Shares

EXACT Sciences Co. (NASDAQ:EXAS) insider Kevin T. Conroy sold 101,488 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the transaction, the insider now owns 931,540 shares in the company, valued at approximately $42,590,008.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

EXACT Sciences Co. (EXAS) traded up $0.04 on Tuesday, hitting $47.57. 1,876,123 shares of the company were exchanged, compared to its average volume of 3,387,089. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. EXACT Sciences Co. has a 12 month low of $18.50 and a 12 month high of $63.60. The firm has a market cap of $5,760.00, a price-to-earnings ratio of -41.37 and a beta of 0.58.

Institutional investors and hedge funds have recently bought and sold shares of the stock. C M Bidwell & Associates Ltd. acquired a new stake in shares of EXACT Sciences in the 4th quarter worth about $117,000. Crow Point Partners LLC bought a new stake in EXACT Sciences in the 4th quarter worth about $145,000. Oppenheimer Asset Management Inc. grew its position in EXACT Sciences by 2,925.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares in the last quarter. Advisory Services Network LLC grew its position in EXACT Sciences by 6,600.0% in the 4th quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock worth $176,000 after purchasing an additional 3,300 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in EXACT Sciences in the 3rd quarter worth about $183,000. Institutional investors own 83.12% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Leerink Swann reiterated an “outperform” rating and set a $67.00 price objective (up previously from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. Robert W. Baird lowered shares of EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price objective on the stock. in a report on Monday, November 13th. Bank of America upped their price objective on shares of EXACT Sciences from $58.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, November 29th. Zacks Investment Research lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, BTIG Research lowered shares of EXACT Sciences from a “buy” rating to a “neutral” rating in a report on Wednesday, November 1st. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $52.84.

ILLEGAL ACTIVITY NOTICE: “EXACT Sciences Co. (EXAS) Insider Kevin T. Conroy Sells 101,488 Shares” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/13/exact-sciences-co-exas-insider-kevin-t-conroy-sells-101488-shares.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply